OncoMatch/Clinical Trials/NCT05570825
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Is NCT05570825 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and CXCR1/2 Inhibitor SX-682 for metastatic lung non-small cell carcinoma.
Treatment: CXCR1/2 Inhibitor SX-682 · Pembrolizumab — This phase II trial tests whether CXCR1/2 inhibitor SX-682 (SX-682) with pembrolizumab works to treat patients with stage IIIC or IV non-small cell lung cancer that has spread to other parts of the body (metastatic) or that has come back (recurrent). SX-682 is a drug that binds to receptors on some types of immune and cancer cells, inhibiting signaling pathways, reducing inflammation, and allowing other types of immune cells to kill and eliminate cancer cells. Pembrolizumab is a monoclonal antibody that binds to a receptor called PD-1 that is found on the surface of T-cells (a type of immune cell), activating an immune response against tumor cells. Giving SX-682 in combination with pembrolizumab may be more effective at treating patients with metastatic or recurrent non-small cell lung cancer than giving these treatments alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
no known oncogenic EGFR mutation
Required: ALK wild-type
no known ... ALK rearrangement
Required: ROS1 wild-type
no known ... ROS1 rearrangement
Required: RET wild-type
no known ... RET rearrangement
Required: PD-L1 (CD274) overexpression (PD-L1 ≥1%)
Tumoral PD-L1 expression ≥1% by any Clinical Laboratory Improvement Act (CLIA)-certified assay
Disease stage
Required: Stage IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: prior chemotherapy in the curative setting allowed if last dose >24 weeks before consenting
Participants must not have received prior chemotherapy ... for metastatic or recurrent NSCLC
Cannot have received: immune checkpoint inhibitor
Exception: prior immune checkpoint inhibitor in the curative setting allowed if last dose >24 weeks before consenting
Participants must not have received prior ... immune checkpoint inhibitor ... for metastatic or recurrent NSCLC
Cannot have received: immune-modulatory therapy (anti-PD[L]1, anti-CTLA4, anti-TIM3, anti-GITR, anti-TIGIT, anti-LAG3)
Exception: prior immune modulatory therapy in the curative setting allowed if last dose >24 weeks before consenting
Participants must not have received prior ... immune-modulatory therapy (e.g. anti-PD[L]1, anti-CTLA4, anti-TIM3, anti-GITR, anti-TIGIT, anti-LAG3), for metastatic or recurrent NSCLC
Lab requirements
Blood counts
Platelet count ≥ 100,000/uL; Absolute neutrophil count ≥ 1,500/uL; Hemoglobin ≥ 8g/dL
Kidney function
Creatinine ≤ 2.0 mg/dL
Liver function
AST and ALT ≤ 2.5 times upper limit of normal
Cardiac function
EKG demonstrating a corrected QT (QTc) interval ≤ 480 msec on three consecutive EKGs; no congenital long QT syndrome
Platelet count ≥ 100,000/uL; Absolute neutrophil count ≥ 1,500/uL; Hemoglobin ≥ 8g/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times upper limit of normal; Creatinine ≤ 2.0 mg/dL; EKG demonstrating a corrected QT (QTc) interval > 480 msec on three consecutive EKGs or patients with congenital long QT syndrome [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify